Policy review demonstrates the inclusion process of statins into the WHO Model List, highlighting strategies to combat global cardiovascular disease.
Although the concept of essential medicines is not new, the processes that lead to placement of these medicines on the World Health Organization Model List of Essential Medicines are not well understood. Here, we describe the process by which we added a class of drugs, statins, to the Model List to help combat the growing global epidemic of cardiovascular disease. Clinical Pharmacology & Therapeutics (2009); 85, 3, 237–239 doi:10.1038/clpt.2008.258
No takes yet. Share an insight, caveat, or question.
Kishore et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: